@article{773e84f6876a4a4983b8c566dce0ff0f,
title = "Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation",
abstract = "The role of hematopoietic cell transplantation (HCT) in the therapy of Hodgkin lymphoma (HL) in pediatric and adult patients is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are included and were reached unanimously by a panel of HL experts. Both autologous and allogeneic HCT offer a survival benefit in selected patients with advanced or relapsed HL and are currently part of standard clinical care. Relapse remains a significant cause of failure after both transplant approaches, and strategies to decrease the risk of relapse remain an important area of investigation.",
keywords = "Allogeneic transplant, Autologous transplant, Hematopoietic cell transplantation, Hodgkin lymphoma",
author = "Perales, {Miguel Angel} and Izaskun Ceberio and Philippe Armand and Burns, {Linda J.} and Robert Chen and Cole, {Peter D.} and Evens, {Andrew M.} and Laport, {Ginna G.} and Moskowitz, {Craig H.} and Uday Popat and Reddy, {Nishitha M.} and Shea, {Thomas C.} and Vose, {Julie M.} and Jeffrey Schriber and Savani, {Bipin N.} and Carpenter, {Paul A.}",
note = "Funding Information: Conflict of interest statement: P.A. received research support from Bristol-Myers Squibb and Merck and consultancy fees from Merck. R.C. received research funding from Merck , Millennium , and Seattle Genetics and honoraria from Millennium and Seattle Genetics. C.H.M. received research support from and served on scientific advisory boards for Merck and Seattle Genetics . M.-A.P. served on an advisory board for Seattle Genetics. N.M.R. received consultancy fees from Celgene, Immunogen, and Pharmacyclics. T.C.S. received research support from Seattle Genetics and served on an advisory board for Spectrum Pharma. J.S. served on an advisory board for Seattle Genetics. The remaining authors have no conflicts of interest to declare. Publisher Copyright: {\textcopyright} 2015 American Society for Blood and Marrow Transplantation.",
year = "2015",
month = jun,
doi = "10.1016/j.bbmt.2015.02.022",
language = "English (US)",
volume = "21",
pages = "971--983",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",
}